Patents Assigned to XenoPort
  • Methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof
    Patent number: 8785443
    Abstract: Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions comprising prodrugs of methyl hydrogen fumarate, and methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis are disclosed.
    Type: Grant
    Filed: October 14, 2011
    Date of Patent: July 22, 2014
    Assignee: XenoPort, Inc.
    Inventors: Archana Gangakhedkar, Xuedong Dai, Noa Zerangue, Peter A. Virsik
  • Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
    Patent number: 8778991
    Abstract: Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions comprising prodrugs of methyl hydrogen fumarate, and methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis are disclosed.
    Type: Grant
    Filed: October 14, 2011
    Date of Patent: July 15, 2014
    Assignee: XenoPort, Inc.
    Inventors: Archana Gangakhedkar, Xuedong Dai, Noa Zerangue, Peter A. Virsik
  • COCRYSTALS OF (N,N-DIETHYLCARBAMOYL)METHYL METHYL (2E)BUT-2-ENE-1,4-DIOATE
    Publication number: 20140179778
    Abstract: Disclosed herein are cocrystals of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, which is a prodrug of methyl hydrogen fumarate.
    Type: Application
    Filed: November 5, 2013
    Publication date: June 26, 2014
    Applicant: XenoPort, Inc.
    Inventors: Chen Mao, Scott L. Childs
  • Levodopa prodrug mesylate hydrate
    Patent number: 8722733
    Abstract: Crystalline (2R)-2-phenylcarbonyloxypropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate, hydrate, methods of making the hydrate, pharmaceutical compositions containing the hydrate, and methods of using the hydrate to treat diseases or disorders such as Parkinson's disease are provided.
    Type: Grant
    Filed: February 18, 2013
    Date of Patent: May 13, 2014
    Assignee: XenoPort, Inc.
    Inventors: Sami Karaborni, Manshiu Leung, Chen Mao, Venkat R. Thalladi
  • Crystalline form of ?-aminobutyric acid analog
    Patent number: 8686034
    Abstract: A crystalline form of a ?-aminobutyric acid analog, and methods of preparing same, are provided.
    Type: Grant
    Filed: June 20, 2011
    Date of Patent: April 1, 2014
    Assignee: XenoPort, Inc.
    Inventors: Tono Estrada, Stephen P. Raillard, Christine Frauenfelder, Uwe Zacher
  • Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof
    Publication number: 20140065211
    Abstract: Improved oral dosage forms of methyl hydrogen fumarate and prodrugs thereof are disclosed. Methods of treating diseases such as multiple sclerosis and psoriasis using such dosage forms are also disclosed.
    Type: Application
    Filed: August 22, 2013
    Publication date: March 6, 2014
    Applicant: XenoPort, Inc.
    Inventors: Sami Karaborni, Sarina Grace Harris Ma, Chen Mao, Ching Wah Chong, Peter Robert Prinz Freed, Mesut Ciper, Stefanie Krenzlin, David J. Wustrow, Peter A. Virsik
  • Anhydrous and Hemihydrate Crystalline Forms of an (R)-Baclofen Prodrug, Methods of Synthesis and Methods of Use
    Publication number: 20140066501
    Abstract: Crystalline (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid anhydrate and crystalline (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid hemihydrate, pharmaceutical compositions comprising such compounds, methods of making and methods of using the same are disclosed.
    Type: Application
    Filed: November 11, 2013
    Publication date: March 6, 2014
    Applicant: XenoPort, Inc.
    Inventors: Stephen P. Raillard, Suresh K. Manthati, Sudhir Joshi
  • Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof
    Publication number: 20140056978
    Abstract: Improved oral dosage forms of methyl hydrogen fumarate and prodrugs thereof are disclosed. Methods of treating diseases such as multiple sclerosis and psoriasis using such dosage forms are also disclosed.
    Type: Application
    Filed: August 22, 2013
    Publication date: February 27, 2014
    Applicant: XenoPort, Inc.
    Inventors: Sami Karaborni, Laura Elizabeth Bauer, Chen Mao, Ching Wah Chong, David J. Wustrow, Peter A. Virsik
  • Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects
    Publication number: 20140057917
    Abstract: Methods of reducing undesirable side effects during therapeutic treatment using monomethyl fumarate and prodrugs of monomethyl fumarate are disclosed.
    Type: Application
    Filed: August 22, 2013
    Publication date: February 27, 2014
    Applicant: XenoPort, Inc.
    Inventors: Kenneth C. Cundy, Sami Karaborni, Peter A. Virsik
  • Oral Dosage Forms Having a High Loading of a Methyl Hydrogen Fumarate Prodrug
    Publication number: 20140056973
    Abstract: Oral dosage forms and granulations with a high loading of a methyl hydrogen fumarate prodrug are disclosed.
    Type: Application
    Filed: August 22, 2013
    Publication date: February 27, 2014
    Applicant: XenoPort, Inc.
    Inventors: Sarina Grace Harris Ma, Laura Elizabeth Bauer, Sami Karaborni, David J. Wustrow, Peter A. Virsik
  • Methods of Use for Monomethyl Fumarate and Prodrugs Thereof
    Publication number: 20140057918
    Abstract: Methods of therapeutic treatment using monomethyl fumarate and prodrugs of monomethyl fumarate are disclosed.
    Type: Application
    Filed: August 22, 2013
    Publication date: February 27, 2014
    Applicant: XenoPort, Inc.
    Inventors: David J. Wustrow, Peter A. Virsik, Mark A. Gallop, Kenneth C. Cundy, Dmitri V. Lissin, Revati Shreeniwas
  • Morpholinoalkyl Fumarate Compounds, Pharmaceutical Compositions, and Methods of Use
    Publication number: 20140051705
    Abstract: Morpholinoalkyl fumarates, pharmaceutical compositions comprising the morpholinoalkyl fumarates, and methods of using morpholinoalkyl fumarates and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis are disclosed.
    Type: Application
    Filed: August 14, 2013
    Publication date: February 20, 2014
    Applicant: XenoPort, Inc.
    Inventors: Kenneth C. Cundy, Suresh K. Manthati, David J. Wustrow
  • Anhydrous and hemihydrate crystalline forms of an ()-baclofen prodrug, methods of synthesis and methods of use
    Patent number: 8580850
    Abstract: Crystalline (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid anhydrate and crystalline (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid hemihydrate, pharmaceutical compositions comprising such compounds, methods of making and methods of using the same are disclosed.
    Type: Grant
    Filed: August 10, 2012
    Date of Patent: November 12, 2013
    Assignee: XenoPort, Inc.
    Inventors: Stephen P. Raillard, Suresh K. Manthati, Sudhir Joshi
  • MORPHOLINOALKYL FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE
    Publication number: 20130203753
    Abstract: Morpholinoalkyl fumarates, pharmaceutical compositions comprising the morpholinoalkyl fumarates, and methods of using morpholinoalkyl fumarates and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis are disclosed.
    Type: Application
    Filed: February 7, 2013
    Publication date: August 8, 2013
    Applicant: XENOPORT, INC.
    Inventor: XENOPORT, INC.
  • LEVODOPA PRODRUG MESYLATE HYDRATE
    Publication number: 20130184344
    Abstract: Crystalline (2R)-2-phenylcarbonyloxypropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate, hydrate, methods of making the hydrate, pharmaceutical compositions containing the hydrate, and methods of using the hydrate to treat diseases or disorders such as Parkinson's disease are provided.
    Type: Application
    Filed: February 18, 2013
    Publication date: July 18, 2013
    Applicant: XenoPort, Inc.
    Inventor: XenoPort, Inc.
  • SYNTHESIS OF ACYLOXYALKYL CARBAMATE PRODRUGS AND INTERMEDIATES THEREOF
    Publication number: 20130131355
    Abstract: Methods for synthesis of 1-(acyloxy)-alkyl carbamates, particularly, the synthesis of 1-(acyloxy)-alkyl carbamate prodrugs of primary or secondary amine-containing drugs are described. Also described are methods for synthesis of 1-(acyloxy)-alkyl N-hydroxysuccinimidyl carbonates which are useful intermediates in the synthesis of 1-(acyloxy)-alkyl carbamates are also described.
    Type: Application
    Filed: January 15, 2013
    Publication date: May 23, 2013
    Applicant: XenoPort, Inc.
    Inventor: XenoPort, Inc.
  • Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
    Patent number: 8435562
    Abstract: Pharmaceutical compositions and oral dosage forms of (2R)-2-phenylcarbonyloxypropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate and methods of treating diseases comprising orally administering such pharmaceutical compositions and dosage forms are disclosed.
    Type: Grant
    Filed: November 8, 2010
    Date of Patent: May 7, 2013
    Assignee: XenoPort, Inc.
    Inventors: Chen Mao, Nikhil Pargaonkar, Laura E. Maurer, Sarina Grace Harris Ma
  • PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF
    Publication number: 20130102641
    Abstract: The present invention provides prodrugs of GABA analogs, pharmaceutical compositions of prodrugs of GABA analogs and methods for making prodrugs of GABA analogs. The present invention also provides methods for using prodrugs of GABA analogs and methods for using pharmaceutical compositions of prodrugs of GABA analogs for treating or preventing common diseases and/or disorders.
    Type: Application
    Filed: December 13, 2012
    Publication date: April 25, 2013
    Applicant: XENOPORT, INC.
    Inventor: XENOPORT, INC.
  • Levodopa prodrug mesylate hydrate
    Patent number: 8399513
    Abstract: Crystalline (2R)-2-phenylcarbonyloxypropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate, hydrate, methods of making the hydrate, pharmaceutical compositions containing the hydrate, and methods of using the hydrate to treat diseases or disorders such as Parkinson's disease are provided.
    Type: Grant
    Filed: October 19, 2009
    Date of Patent: March 19, 2013
    Assignee: XenoPort, Inc.
    Inventors: Sami Karaborni, Manshiu Leung, Chen Mao, Venkat Thalladi
  • Use of (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl) butanoic acid for treating urinary incontinence
    Patent number: 8377956
    Abstract: Use of (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid for treating urinary incontinence is disclosed.
    Type: Grant
    Filed: March 1, 2011
    Date of Patent: February 19, 2013
    Assignee: XenoPort, Inc.
    Inventors: Aetna W. Wun, David J. Wustrow